For depression and/or anxiety. ANDA 211618, held by Velzen Pharma Pvt. Doxepin Hydrochloride.
As of Nov 16, 2026, ANDA 211618 (Doxepin Hydrochloride), held by Velzen Pharma Pvt, was first approved by FDA on Mar 1, 2021, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Doxepin Hydrochloride is recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 1, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxepin HydrochlorideEQ 150MG BASE · capsule;oral | Doxepin Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters